90 cents is the price target, page-47

Our future customers/licensees/owner(s):- (apologies for formatting)

The top 20 pharma companies by 2020 revenue

· 1. Johnson & Johnson – $83 billion (Stelara - Crohns disease - J&J’s top-selling drug bysales, pulling in $7.7 billion).

· 2. Roche - $58 billion (PD-L1 Tecentriq up 55% to $2.8b).

· 3. Novartis - $49 billion (Novartis won U.S. clearance for Tabrecta in non-smallcell lung cancer with MET exon 14 skipping mutations, which make up about 3% to4% of newly diagnosed NSCLC cases).

· 4. Merck & Co. - $47 billion (Keytruda $14.4 billion in 2020, Keytruda’s sales jumped 30%,keeping it on track to be the world’s best-selling drug in the middle of this decade).

· 5. AbbVie - $46 billion (Immunology remains AbbVie’s bread and butter. Versatile mega-blockbuster Humira * ($19.8 billion).

· 6. GlaxoSmithKline- $44 billion (GSK has also made a major push into oncology R&D, butthat effort hasn’t yielded high returns).

· 7. Bristol Myers Squibb - $43 billion (Revlimid, generated $12.1b and Yervoy $1.7b. Sales ofimmuno-oncology treatment Opdivo fell by 3% to $7 billion as the PD-1inhibitor continued to face tough competition from Merck & Co.'s rivalKeytruda. There were some research disappointments, too, including a study thatshowed that pairing Opdivo with chemotherapy produced no better outcome thandid chemotherapy alone for non-squamous non-small cell lungcancer.

· 8. Pfizer- $42 billion (Ibrance HER breast cancer – CDK4 inhibitor) was up 9% with $5.39 billion.

· 9. Sanofi - $41 billion (strategy, unveiled in December 2019, entailed focusing on products and therapeutic areas where Sanofi had the best shot of succeeding. That included immunology.

· 10. Takeda - $29 billion (Takeda’s oncology portfolio chalked up both wins and losses in 2020. Alunbrig got the U.S. green light to reach patients with previously untreatedALK-positive non-small cell lung cancer.

*Humira is an anti-TNF monoclonalantibody that currently treats Crohn's disease, rheumatoid arthritis,ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis.